Amylyx Pharmaceuticals Stock News
$9.30
10.32%
day before yesterday
NYSE,
Aug 22, 10:01 pm CET
Industry
Amylyx Pharmaceuticals Stock News
Neutral
Seeking Alpha
●
16 days ago
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Camille L. Bedrosian - Chief Medical Officer James M.
Neutral
The Motley Fool
●
17 days ago
Amylyx (AMLX) Q2 Net Loss Narrows 43%
Neutral
Business Wire
●
17 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results.
Neutral
Business Wire
●
24 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025.
Neutral
Seeking Alpha
●
about one month ago
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential
Neutral
GlobeNewsWire
●
about one month ago
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Amylyx (AMLX) To Contact Him Directly To Discuss Their Options
Neutral
Business Wire
●
about one month ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine So...
Neutral
Business Wire
●
about 2 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
